Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective

References

• Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150(7):1579–1589.e2. doi: 10.1053/j.gastro.2016.02.026.
   PubMed Web of Science ®Google Scholar
• Erly B, Carey WD, Kapoor B, et al. Hepatorenal syndrome: a review of pathophysiology and current treatment options. Semin Intervent Radiol. 2015;32(4):445–454. doi: 10.1055/s-0035-1564794.
   PubMed Web of Science ®Google Scholar
• Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–1318.
   PubMed Web of Science ®Google Scholar
• Jamil K, Huang X, Lovelace B, et al. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ. 2019;22(5):421–429. doi: 10.1080/13696998.2019.1580201.
   PubMed Web of Science ®Google Scholar
• Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236.
   PubMed Web of Science ®Google Scholar
• Pant C, Jani BS, Desai M, et al. Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the nationwide inpatient sample 2002-2012. J Investig Med. 2016;64(1):33–38. doi: 10.1136/jim-d-15-00181.
   PubMed Web of Science ®Google Scholar
• US Census Bureau. Quick facts 2021 [cited 2022 Nov 29]. Available from: https://www.census.gov/quickfacts/fact/table/US/TST045218.
   Google Scholar
• Angeli P, Bernardi M, Villanueva C, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi: 10.1016/j.jhep.2018.03.024.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol. 2022;117(2):225–252. doi: 10.14309/ajg.0000000000001595.
   PubMed Web of Science ®Google Scholar
• Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the study of liver diseases. Hepatology. 2021;74(2):1014–1048. doi: 10.1002/hep.31884.
   PubMed Web of Science ®Google Scholar
• Acevedo JG, Cramp ME. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol. 2017;9(6):293–299.
   Google Scholar
• Glass L, Sharma P. Evidence-based therapeutic options for hepatorenal syndrome. Gastroenterology. 2016;150(4):1031–1033.
   Google Scholar
• O'Leary JG, Levitsky J, Wong F, et al. Protecting the kidney in liver transplant candidates: Practice-Based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016;16(9):2516–2531.
   Google Scholar
• Papaluca T, Gow P. Terlipressin: Current and emerging indications in chronic liver1. Acevedo JG, Cramp ME. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol. 2017;9(6):293–299.
   Google Scholar
• Sanyal AJR, Brown KA, Landis CS, et al. Hepatorenal syndrome patient characteristics, treatment, and clinical response by disease severity: real-world practice patterns from 11 US hospitals. American Association for the Study of Liver Disease (AASLD) Annual Meeting, November 12–15, 2021; Virtual.
   Google Scholar
• Mallinckrodt Pharmaceuticals. Data on File. Clinical study report: a multi-center, randomized, placebo-controlled, double-blind study to confirm efficacy and safety of terlipressen in subjects with hepatorenal syndrome type 1 (The CONFIRM Study), 2020.
   Google Scholar
• Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62(2):567–574. doi: 10.1002/hep.27709.
   PubMed Web of Science ®Google Scholar
• Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71(2):600–610. doi: 10.1002/hep.30208.
   PubMed Web of Science ®Google Scholar
• Nayyar S, Kaur R, Mohan G, et al. A prospective study to compare the efficacy of noradrenaline verses terlipressin in hepatorenal syndrome in patients with advanced cirrhosis. Int J Adv Med. 2021;8(9):7.
   Google Scholar
• Saif RU, Dar HA, Sofi SM, et al. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study. Indian J Gastroenterol. 2018;37(5):424–429. doi: 10.1007/s12664-018-0876-3.
   PubMed Web of Science ®Google Scholar
• Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293–1298. doi: 10.1016/j.jhep.2012.01.012.
   PubMed Web of Science ®Google Scholar
• Mallinckrodt Pharmaceuticals. TERLIVAZ [package insert]; Bedminster, NJ. 2022.
   Google Scholar
• Pitre T, Kiflen M, Helmeczi W, et al. The comparative effectiveness of vasoactive treatments for hepatorenal syndrome: a systematic review and network meta-analysis. Crit Care Med. 2022;50(10):1419–1429. doi: 10.1097/CCM.0000000000005595.
   PubMed Web of Science ®Google Scholar
• Red Book Online (2021) [Internet]. 2021.
   Google Scholar
• Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818–828. doi: 10.1056/NEJMoa2008290.
   PubMed Web of Science ®Google Scholar
• El-Desoki Mahmoud EI, Abdelaziz DH, Abd-Elsalam S, et al. Norepinephrine is more effective than midodrine/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial. Front Pharmacol. 2021;12:675948. doi: 10.3389/fphar.2021.675948.
   PubMed Web of Science ®Google Scholar
• Mallinckrodt Pharmaceuticals. Data on File. Average AE (identified by DX codes) per-Day Cost per Outpatient Encounter from MarketScan Database. 2022.
   Google Scholar